Recombinant Mouse E3 ubiquitin-protein ligase RNF182 (Rnf182)

What is the basic structure of RNF182 and what functional domains does it contain?

RNF182 contains a typical C3HC4-type RING finger domain located between amino acids C20 and C67, which is essential for its E3 ubiquitin ligase activity. The protein also features two putative transmembrane helices at the C-terminus (spanning amino acids 178-200 and 212-234) and four leucine repeats between amino acids 197 and 225. The primary structure is highly conserved across species, with human RNF182 showing 98% and 97% sequence identity to mouse and rat homologs, respectively .

What is the tissue distribution and expression pattern of RNF182?

RNF182 is primarily a brain-enriched protein with low abundance in normal conditions. Through semi-quantitative RT-PCR analysis, RNF182 expression has been detected in mouse cortex, hippocampus, cerebellum, and spinal cord, but not in heart, liver, kidney, or skeletal muscle . The protein is weakly expressed under normal conditions but can be significantly upregulated in response to cellular stress or during differentiation processes.

What is the subcellular localization of RNF182?

RNF182 primarily localizes in the cytoplasm, with a punctuated pattern observed particularly in cytoplasmic and perinuclear regions. Co-localization studies with binding partners such as ATP6V0C have confirmed this cytoplasmic distribution pattern . This localization is consistent with its role in protein degradation via the ubiquitin-proteasome pathway.

What cellular models are most suitable for studying RNF182 function?

Several cellular models have proven effective for RNF182 research:

The choice of model depends on the specific research questions. For neurodegeneration studies, neuronal models are preferred, while macrophages are more suitable for investigating immune regulation functions .

What are the established methods to assess RNF182 E3 ligase activity?

In vitro ubiquitination assays represent the gold standard for assessing RNF182 E3 ligase activity. This typically involves:

• Expression and purification of recombinant RNF182 (His-tagged or GST-tagged)

• Setting up reaction mixtures containing:

  • Purified E1 enzyme

  • Appropriate E2 conjugating enzyme

  • Ubiquitin

  • ATP regeneration system

  • RNF182 protein

• Incubation and detection of ubiquitination by Western blotting

RNF182 has been demonstrated to function as a substrate-independent, E2-dependent E3 ubiquitin ligase. Control reactions omitting E1, E2, E3, or ubiquitin are essential to validate results . For substrate-specific ubiquitination studies, purified potential substrates (such as ATP6V0C or p65) should be included in the reaction mixture.

How can RNF182 expression be efficiently modulated for functional studies?

Several approaches have been validated for modulating RNF182 expression:

For neuronal models, plasmid transfection efficiency should be optimized, as these cells can be challenging to transfect. The timing of expression modulation is critical, particularly when studying stress responses or cell death mechanisms .

What are the validated protein interactions of RNF182, and how should researchers investigate new potential interactions?

RNF182 has been confirmed to interact with:

• ATP6V0C - a component involved in gap junction complexes and neurotransmitter release channels

• p65 (RelA) - a key component of the NF-κB signaling pathway

To investigate new potential interactions, researchers should employ a multi-method approach:

• Initial screening via yeast two-hybrid assays

• Validation through co-immunoprecipitation in relevant cell types

• Confirmation of subcellular co-localization using immunofluorescence microscopy

• Functional validation through domain mapping and mutagenesis studies

The interaction with ATP6V0C does not require the RING finger domain, suggesting that different domains of RNF182 may mediate distinct protein interactions .

How does RNF182 regulate protein degradation, and what are its confirmed substrates?

RNF182 facilitates protein degradation through the ubiquitin-proteasome pathway by promoting K48-linked polyubiquitination of target proteins. Confirmed substrates include:

The degradation process involves:

• Physical interaction between RNF182 and substrate

• E2-dependent K48-linked polyubiquitination catalyzed by RNF182

• Recognition and degradation of ubiquitinated substrates by the 26S proteasome

This activity can be validated using proteasome inhibitors (e.g., MG132) to demonstrate accumulation of ubiquitinated substrates .

What signaling pathways are known to regulate RNF182 expression?

RNF182 expression is regulated by various stress and differentiation signals:

• Neuronal differentiation: Upregulated during retinoic acid-induced differentiation of human NT2 cells

• Cellular stress responses:

  • Significantly increased in neuronal cells subjected to oxygen and glucose deprivation (OGD)

  • Further elevated when β-amyloid peptide is added during OGD treatment

• TLR signaling: Specifically upregulated by TLR stimuli (TLR4, TLR3, and TLR9 agonists) in macrophages

This regulation appears to be transcriptional, as changes in mRNA levels precede protein accumulation. The specific transcription factors mediating these responses require further investigation .

What is the evidence for RNF182 involvement in Alzheimer's disease pathogenesis?

Multiple lines of evidence support RNF182 involvement in Alzheimer's disease (AD):

• Expression studies:

  • Consistently higher RNF182 transcript levels in AD brain samples compared to age-matched controls

  • Validated in both pooled RNA and individual brain samples from tissue banks

• Cellular response patterns:

  • Upregulation in neuronal cells subjected to AD-relevant stressors, including oxygen-glucose deprivation and β-amyloid peptide exposure

  • The combination of these stressors produced synergistic upregulation of RNF182

• Functional consequences:

  • Overexpression of RNF182 alone triggered cell death in neuronal models

  • RNF182-mediated degradation of ATP6V0C may disrupt gap junction complexes and neurotransmitter release

These findings suggest RNF182 may participate in neurodegeneration cascades, potentially through disruption of neuronal communication and/or direct promotion of cell death pathways .

How does RNF182 contribute to neuronal cell death, and what approaches can be used to study this function?

RNF182 appears to promote neuronal cell death through multiple mechanisms:

• Direct effect: Overexpression of RNF182 alone is sufficient to reduce neuronal cell viability

• Substrate regulation: Degradation of ATP6V0C may impair neuronal function and resilience

• Stress amplification: RNF182 expression increases in response to cellular stress, potentially creating a positive feedback loop

To study these mechanisms effectively, researchers should:

Importantly, downregulation of endogenous RNF182 significantly reduced cell death caused by OGD treatment, suggesting potential neuroprotective strategies .

How does RNF182 regulate TLR signaling and inflammatory responses?

RNF182 functions as a feedback-negative regulator of TLR signaling through the following mechanism:

• TLR stimulation (via TLR4, TLR3, or TLR9 agonists) upregulates RNF182 expression in macrophages

• RNF182 physically interacts with p65 (RelA), a key component of NF-κB signaling

• This interaction facilitates K48-linked polyubiquitination of p65

• Ubiquitinated p65 undergoes proteasomal degradation

• Reduced p65 levels inhibit TLR-triggered proinflammatory cytokine production

This mechanism provides a feedback loop to limit excessive inflammation following TLR activation. Importantly, RNF182 selectively affects proinflammatory cytokine production without influencing type I interferon responses, distinguishing it from other RNF family proteins .

What experimental approaches are most suitable for studying RNF182's role in inflammation?

To comprehensively study RNF182's role in inflammation:

When designing these experiments, researchers should consider the temporal dynamics of inflammation, as RNF182's role appears to be in the resolution/limitation phase rather than the initiation phase .

How does RNF182 selectively regulate proinflammatory cytokines without affecting type I interferons?

This selective regulation represents an intriguing aspect of RNF182 function:

• Knockdown of RNF182 amplifies production of proinflammatory cytokines (e.g., TNF, IL-6) but not type I interferons following TLR stimulation

• This selectivity occurs despite both pathways being downstream of TLR activation

• The mechanism appears to involve specific targeting of the NF-κB pathway (through p65 degradation) while sparing IRF3/7-dependent pathways

This dichotomy suggests RNF182 fine-tunes rather than broadly suppresses innate immune responses. Researchers investigating this selectivity should:

• Compare effects on canonical vs. non-canonical NF-κB pathways

• Assess impacts on specific transcription factor complexes at proinflammatory gene promoters

• Examine potential compartmentalization of RNF182 activity in cellular subdomains

What is the potential therapeutic relevance of modulating RNF182 in neurological and inflammatory conditions?

The dual role of RNF182 in neurodegeneration and inflammation presents interesting therapeutic possibilities:

The development of small molecule modulators of RNF182 activity or substrate recognition would represent an important advance. Additionally, tissue-specific targeting strategies would help address the potentially opposing effects in different cell types .

How might researchers resolve the apparent paradox of RNF182 being protective in inflammation but detrimental in neurodegeneration?

This paradox represents a complex research challenge:

• Cell-type specificity: RNF182 may target different substrates in neurons vs. immune cells

• Context-dependent functions: The same molecular mechanism may have different outcomes depending on cellular context

• Temporal dynamics: Acute vs. chronic upregulation may lead to distinct consequences

• Substrate availability: The relative abundance of ATP6V0C vs. p65 may differ between cell types

To address this paradox, investigators should:

• Perform comprehensive substrate identification in different cell types using proteomics approaches

• Develop cell-type specific knockout models to separate neuronal from immunological functions

• Examine temporal dynamics of RNF182 function using inducible systems

• Investigate potential regulators of RNF182 substrate specificity

What technical challenges remain in studying RNF182, and how might they be overcome?

Several technical challenges complicate RNF182 research:

Future technological advances including CRISPR-based endogenous tagging, improved mass spectrometry for ubiquitination site mapping, and development of specific small molecule inhibitors would significantly advance the field .